Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
The calculated recall values show that TAMBOOR can predict more than half of the known positives.The high-confidence metabolite level changes for PD compiled from the literature, with references of the supporting studies.Metabolites (Increased)Detected bySupporting referencesQuinolinateOriginal TIMBR49,50KynurenineOriginal TIMBR51,52Fe3 + Original TIMBR53,54HydroxideOriginal TIMBR55,56ProstaglandinsOriginal TIMBR57,58SalsolinolTAMBOOR59,601,2-dehydrosalsolinolTAMBOOR61,62AcetoneTAMBOOR63,64Vanil-LactateTAMBOOR65,66FormateTAMBOOR63,67UreaTAMBOOR68,69(R)-mevalonateTAMBOOR70,71BiliverdinTAMBOOR69,724-methyl-2-oxopentanoateOriginal TIMBR & TAMBOOR73,74Metabolites (Decreased)Detected byApoA1 (Apolipoprotein A1)Original TIMBR75,765-hydroxyindoleacetateOriginal TIMBR77,78LanosterolOriginal TIMBR79,803-methoxytyramineOriginal TIMBR81,82LysineModified TIMBR83,84GSH (Glutathione)Modified TIMBR85,86Calcitriol (Vitamin D)TAMBOOR87,88NicotinamideTAMBOOR89,90CarnosineTAMBOOR91,92AlbuminOriginal TIMBR & TAMBOOR93,94Thiamin-PALL95,96The number of predictions, true positive values, and calculated statistical metrics for each biomarker prediction approach considered in the study.Original TIMBRModified TIMBRTAMBOORNumber of predicted biomarkers (increased secretion)184178118Number of predicted biomarkers (decreased secretion)185121156Total number of predicted biomarkers369299273Number of high confidence markers in predictions12314Number of well known markers in predictions313Total True Positives15417Precision = TP/(TP + FP)0.0410.0130.062Recall = TP/(TP* + FN**)0.4840.1330.567TP true positive, FP false positive, FN false negative.*TP: Number of high confidence markers in predictions + Number of well known markers in predictions.**FN: (Number of high confidence markers + Number of well known markers = 30): TP.
Source: Comparative evaluation of biomarker prediction approaches. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Briefly, transcriptome data from controls and PD patients were separately mapped on the human genome-scale metabolic network, Human-GEM, using GPR (gene-protein-reaction) rules defined in the model for each reaction.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Transcriptome-based biomarker prediction for Parkinson’s disease using genome-scale metabolic modeling
Study design awaiting verification · Scientific Reports · 2024
Original publication title
Transcriptome-based biomarker prediction for Parkinson’s disease using genome-scale metabolic modeling
© The Author(s) 2024
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Parkinson's disease (PD) is the second most common neurodegenerative disease in the world. Identification of PD biomarkers is crucial for early diagnosis and to develop target-based therapeutic agents. Integrative analysis of genome-scale metabolic models (GEMs) and omics data provides a computational approach for the prediction of metabolite biomarkers. Here, we applied the TIMBR (Transcriptionally Inferred Metabolic Biomarker Response) algorithm and two modified versions of TIMBR to investigate potential metabolite biomarkers for PD. To this end, we mapped thirteen post-mortem PD transcriptome datasets from the substantia nigra region onto Human-GEM.
We considered a metabolite as a candidate biomarker if its production was predicted to be more efficient by a TIMBR-family algorithm in control or PD case for the majority of the datasets. Different metrics based on well-known PD-related metabolite alterations, PD-associated pathways, and a list of 25 high-confidence PD metabolite biomarkers compiled from the literature were used to compare the prediction performance of the three algorithms tested. The modified algorithm with the highest prediction power based on the metrics was called TAMBOOR, TrAnscriptome-based Metabolite Biomarkers by On: Off Reactions, which was introduced for the first time in this study.
TAMBOOR performed better in terms of capturing well-known pathway alterations and metabolite secretion changes in PD. Therefore, our tool has a strong potential to be used for the prediction of novel diagnostic biomarkers for human diseases.
Authors’ abstract
Parkinson's disease (PD) is the second most common neurodegenerative disease in the world. Identification of PD biomarkers is crucial for early diagnosis and to develop target-based therapeutic agents. Integrative analysis of genome-scale metabolic models (GEMs) and omics data provides a computational approach for the prediction of metabolite biomarkers. Here, we applied the TIMBR (Transcriptionally Inferred Metabolic Biomarker Response) algorithm and two modified versions of TIMBR to investigate potential metabolite biomarkers for PD. To this end, we mapped thirteen post-mortem PD transcriptome datasets from the substantia nigra region onto Human-GEM.
We considered a metabolite as a candidate biomarker if its production was predicted to be more efficient by a TIMBR-family algorithm in control or PD case for the majority of the datasets. Different metrics based on well-known PD-related metabolite alterations, PD-associated pathways, and a list of 25 high-confidence PD metabolite biomarkers compiled from the literature were used to compare the prediction performance of the three algorithms tested. The modified algorithm with the highest prediction power based on the metrics was called TAMBOOR, TrAnscriptome-based Metabolite Biomarkers by On: Off Reactions, which was introduced for the first time in this study.
TAMBOOR performed better in terms of capturing well-known pathway alterations and metabolite secretion changes in PD. Therefore, our tool has a strong potential to be used for the prediction of novel diagnostic biomarkers for human diseases.
Publication and source details
Original title: Transcriptome-based biomarker prediction for Parkinson’s disease using genome-scale metabolic modeling
Ecehan Abdik; Tunahan Çakır
Scientific Reports · 2024
© The Author(s) 2024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T13:42:26.538632+00:00
DOI: 10.1038/s41598-023-51034-y · PMC10770157